Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: Does the addition of systemic bevacizumab improve results?

Oncology

Volumn 80, Issue 3-4, 2011, Pages 153-159

  Kemeny, Nancy E ^a,b   Schwartz, Lawrence ^a   Gönen, Mithat ^a   Yopp, Adam ^b   Gultekin, David ^a   D'Angelica, Michael I ^b   Fong, Yuman ^b   Haviland, Dana ^b   Gewirtz, Alexandra N ^a   Allen, Peter ^b   Jarnagin, William R ^b  

^a Department of Medicine ^*  (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Floxuridine; Hepatic arterial infusion; Hepatocellular carcinoma; Intrahepatic cholangiocarcinoma

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; DEXAMETHASONE; ERLOTINIB; FLOXURIDINE; GEMCITABINE; IRINOTECAN;

AGED; ARTICLE; BILE DUCT CARCINOMA; BILIRUBIN BLOOD LEVEL; CANCER SURVIVAL; CONFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DUODENUM DISEASE; FEMALE; HEART INFARCTION; HEPATIC ARTERY; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; LIVER CANCER; LIVER CELL CARCINOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STENT; SYNCOPE; THROMBOCYTOPENIA; THROMBOSIS;

AGED; ALKALINE PHOSPHATASE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; DEXAMETHASONE; DISEASE-FREE SURVIVAL; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; FLOXURIDINE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 79958772542     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000324704     Document Type: Article

References (28)

1. Shaib YH, Davila JA, McGlynn K, et al: Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase J Hepatol 2004; 40: 472-477. (Pubitemid 38230849)
2. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Fan ST, Lo CM, Liu CL, et al: Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999; 229: 322-330.
4. Fong Y, Sun RL, Jarnagin W, et al: An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999; 229: 790-799.
5. El Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States (see comments). N Engl J Med 1999; 340: 745-750. (Pubitemid 29114292)
6. Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-1357. (Pubitemid 32496970)
7. Weber SM, Jarnagin WR, Klimstra D, et al: Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 2001; 193: 384-391. (Pubitemid 32895979)
8. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
9. Valle JW, Wasan H, Palmer D, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281.
10. Atiq OT, Kemeny N, Niedzwieki D, et al: Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin c through an implantable pump. Cancer 1992; 69: 920-924.
11. Seeger J, Woodcock TM, Blumenreich MS, et al: Hepatic perfusion with FUdR utilizing an implantable system in patients with liver primary cancer or metastatic cancer confined to the liver. Cancer Invest 1989; 7: 1-6. (Pubitemid 19192620)
12. Clavien PA, Selzner N, Morse M, et al: Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery 2002; 131: 433-442. (Pubitemid 34289734)
13. Venook AP, Warren RS: Regional chemotherapy approaches for primary and metastatic liver tumors. Surg Oncol Clin North Am 1996; 5: 411-427. (Pubitemid 26132360)
14. Meric F, Patt YZ, Curley SA, et al: Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 2000; 7: 490-495. (Pubitemid 30666487)
15. Smith GW, Bukowski RM, Hewlett JS, et al: Hepatic artery infusion of 5-fluorouracil and mitomycin C in cholangiocarcinoma and gallbladder carcinoma. Cancer 1984; 54: 1513-1516. (Pubitemid 14006207)
16. Jarnagin WR, Schwartz LH, Gultekin DH, Gönen M, et al: Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 2009; 20: 1589-1595.
17. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62. (Pubitemid 40093472)
18. Kemeny N, Daly J, Oderman P, et al: Hepatic artery pump infusion toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol 1984; 2: 595-600. (Pubitemid 14025614)
19. National Cancer Institute: Common Terminology Criteria for Adverse Events v 3.0 (CTCAE), 9 August 2006. http://ctep.cancer. gov/protocoldevelopment/ electroniC-appli cations/docs/ctcaev3.pdf.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
21. Power D, Capanu M, Patel D, et al: Unexpected increased biliary toxicity when systemic bevacizumab is added to hepatic arterial infusion. J Clin Oncol 2010; 28(suppl):3559.
22. Huitzil-Melendez FD, O'Reilly EM, Duffy A, et al: Indications for neoadjuvant, adjuvant, and palliative chemotherapy in the treatment of biliary tract cancers. Surg Oncol Clin N Am 2009; 18: 361-379.
23. Kemeny NE, Melendez FD, Capanu M, et al: Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009; 27: 3465-3471.
24. Kemeny N, Huang Y, Cohen AM, et al: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341: 2039-2048. (Pubitemid 30035952)
25. Kemeny N, Gonen M: Hepatic arterial infusion after liver resection. N Engl J Med 2005; 352: 734-735. (Pubitemid 40239230)
26. Kemeny N, Jarnagin W, Capanu M, et al: A randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol, E-pub ahead of print.
27. Traina TA, Norton L, Drucker K, et al: Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer. Oncologist 2006; 11: 1070-1071. (Pubitemid 44788397)
28. Spigel DR, Hainsworth JD, Yardley DA, et al: Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010; 28: 43-48.